SPRC logo

SCISPARC LTD

SPRCNASDAQ
🏆 #5295 by market capUS Equity
$787.11▲ $61.16 (+7.77%)
Simulated price
🔔
Track SPRC
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 7.8%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$3M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
2.3x
Cheap
Otter Score
60
Fair
No chart data available for SPRC.

Trading Snapshot

Day Range
$777.60 – $796.29
52-Week Range
$2.98 – $80.10
Volume
$4.00B
Avg Volume
$5.24B
Shares Outstanding
570,000
Next Earnings
Nov 6, 2026

Fundamentals Snapshot

Annual Revenue
$856,000
Last Q Revenue
$395,000
P/E Ratio
—
P/S Ratio
2.3x
EPS (TTM)
$-461.25
Dividend Yield
—
Dilution (1yr)
−82.0%

Why Investors Own SPRC

  • ✓High-growth profile — revenue up -3.0% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 44% gross margin and 19% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

SPRC logo

SCISPARC LTD

SPRC
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$856K▼ −34.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
73.7%▲ +90.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$9M▲ +19.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$4M▼ −18.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
41K▼ −82.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$4M▲ +$3M YoY
StockOtter · stockotter.space

About SCISPARC LTD

SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy. The company has formed strategic alliances to further its goals. A partnership with Procaps focuses on the development and eventual commercial manufacturing of SCI-110, as well as CannAmide, an oral palmitoylethanolamide in a soft gel capsule. SciSparc is also collaborating with the Sheba Fund for Health Services and Research to explore SCI-210's potential in managing status epilepticus. Additionally, it has teamed up with The Israeli Medical Center for Alzheimer's to conduct a Phase IIa clinical trial, evaluating the safety, tolerability, and effectiveness of SCI-110 for patients experiencing Alzheimer's disease and agitation. Founded in 2004, the company initially operated under the name Therapix Biosciences Ltd. before changing to SciSparc Ltd. in January 2021. Its main corporate office is located in Tel Aviv-Yafo, Israel.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Price Target

ⓘ
Average Target
$853.93
▲ +8.5% Upside
High Target$1,055.00
Low Target$725.78
Based on 27 analysts

Latest News & Updates

🚀
Reuters·2h ago

SCISPARC LTD tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift SPRC price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

SCISPARC LTD announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.